EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

Contributed by: PR Newswire

Tags

EADV

More Like This

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

UEG Week: Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetes

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Business Wire logo

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

GlobeNewswire associated0

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference